OrthoPediatrics (KIDS) Projected to Announce Quarterly Earnings on Tuesday

OrthoPediatrics (NASDAQ:KIDS) is anticipated to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.31) per share and revenue of $68.21 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. The business had revenue of $59.36 million for the quarter, compared to the consensus estimate of $58.28 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Stock Up 0.4%

Shares of NASDAQ KIDS opened at $20.19 on Friday. The company’s 50-day simple moving average is $18.97 and its 200-day simple moving average is $17.80. OrthoPediatrics has a 52-week low of $14.42 and a 52-week high of $22.80. The firm has a market cap of $518.48 million, a price-to-earnings ratio of -12.02 and a beta of 0.99. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29.

Analyst Ratings Changes

Several research firms recently weighed in on KIDS. Canaccord Genuity Group set a $25.00 price target on shares of OrthoPediatrics in a research report on Friday, April 24th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Truist Financial boosted their price objective on OrthoPediatrics from $17.00 to $20.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. BTIG Research reissued a “buy” rating and set a $24.00 target price on shares of OrthoPediatrics in a report on Friday, May 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.78.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its position in OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after acquiring an additional 452,840 shares during the last quarter. Vanguard Group Inc. grew its stake in OrthoPediatrics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after acquiring an additional 10,927 shares in the last quarter. Marshall Wace LLP raised its holdings in OrthoPediatrics by 6.0% in the 3rd quarter. Marshall Wace LLP now owns 444,320 shares of the company’s stock valued at $8,233,000 after acquiring an additional 25,191 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in OrthoPediatrics by 303.3% in the 4th quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock worth $3,542,000 after purchasing an additional 150,000 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.